Kotak Institutional Equities remains positive about the Indian pharmaceutical sector, even as US tariff uncertainties loom. They believe leading companies like Sun Pharma, Lupin, and Cipla are well-prepared to navigate these challenges. The brokerage notes that while potential tariffs may lower export margins, Indian generic drugs remain affordable and essential, which can help mitigate losses.
Kotak highlights the resilience of these firms. Their diverse product portfolios, strong domestic sales, and continuous investment in research and development keep them competitive. Cost-effective manufacturing further strengthens their position in global markets, allowing them to absorb possible tariff shocks.
In addition, the growing demand for Indian pharmaceutical products, both locally and internationally, adds to their strength. Despite challenges in international markets, these companies continue to expand and innovate. Kotak believes their adaptability and strategic planning will help them overcome short-term setbacks and maintain long-term growth.
While US tariff concerns create some uncertainty, Kotak Institutional Equities remains confident in the sector’s strong fundamentals. They see Indian pharmaceutical companies as well-positioned for future success, making them attractive investment options for long-term gains.
